27/07/2017 Revenue at June 30, 2017: Satisfactory activity growth

Guerbet is publishing revenue of €407.1 million for the 1st half-year of 2017, up 8.1% at current exchange rates and 5.6% at constant exchange rates (CER). In the second quarter, published revenue stood at €204.0 million, up 5.7% at current exchange rates and 3.8% at CER.


10/07/2017 Guerbet announces plans to streamline its contrast media portfolio

Guerbet announced today that it will phase out sales throughout the world of two products: Hexabrix® (meglumine and sodium ioxaglate) and Optimark® (gadoversetamide).


22/06/2017 MLCTO 2017: Guerbet, a partner in the initiatives implemented for interventional cardiologists

MLCTO 2017 │ from June 29 to July 1 │ Hyatt Regency │ Palais de la Méditerranée │ Nice (France)


22/06/2017 APPLE 2017: Guerbet implicated in the fight against liver cancer

APPLE 2017 │ from July 14 to 16 │ Grand Copthorne Waterfront Hotel │ Singapore


14/06/2017 Guerbet invests in the Truffle Capital fund dedicated to medical devices and biotechnologies

Guerbet today announced that it has signed an equity acquisition of fifteen million Euros in the BioMedTech fund (FPCI) managed by Truffle Capital


09/06/2017 ESGAR 2017: Guerbet active and implicated in abdominal and gastrointestinal radiology

ESGAR 2017 │ from June 20 to 23 │ Megaron Athens International Conference Centre │ Athens (Greece)


29/05/2017 GEST 2017: Guerbet to meet with interventional radiologists

GEST 2017 │ Stand No. 12 │ from May 31 to June 3 │ Firenze Fiera Congress and Exhibition Centre│ Florence (Italy)


Displaying results ###SPAN_BEGIN###%s to %s out of ###SPAN_BEGIN###%s
<< First < Previous 1-7 8-14 15-20 Next > Last >>